Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 677 across all filing types
Latest filing 2026-04-29 Declaration of Voting R…
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Resolutions at BioInvent’s Annual General Meeting 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release summarizing the resolutions adopted at BioInvent’s Annual General Meeting 2026, including election of board members, approval of financial statements, fee resolutions, incentive programs, share issues, and authorizations. It reports the outcomes of shareholder votes and formal AGM resolutions. This aligns with "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2026-04-29 English
Beslut på BioInvents årsstämma 2026
AGM Information Classification · 94% confidence The document is a press release summarizing the resolutions and decisions taken at BioInvent’s 2026 Annual General Meeting, including board elections, approval of financial statements, discharge of liability, auditor appointment, incentive program approvals, and share issuance authorizations. This matches the definition of AGM Information (materials and outcomes from an AGM).
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 90% confidence The document is titled “Delårsrapport 1 januari – 31 mars 2026” (Interim Report for January 1 – March 31, 2026). It contains detailed financial tables for the first quarter, management commentary (VD comments), operational and clinical program updates, and outlook – all hallmarks of a comprehensive quarterly interim report rather than an announcement or presentation. Therefore, it fits the Interim / Quarterly Report category. Q1 2026
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 92% confidence The document is titled “Interim Report January 1 – March 31, 2026” for BioInvent International AB (publ), covering first quarter financial performance. It includes actual financial statements (net sales, profit/loss, cash flows), detailed management commentary (CEO comments), business highlights, and clinical program updates. This matches the definition of an Interim/Quarterly Report (IR), not merely an announcement or presentation. Hence, it should be classified as IR. Q1 2026
2026-04-29 English
Annual Report (ESEF) 2025
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-03-31 Swedish
Kallelse till årsstämma i BioInvent International AB
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a detailed notice ("Kallelse till årsstämma") of BioInvent International AB’s Annual General Meeting, including agenda items, proposals for resolutions, voting procedures, and proxy arrangements. It is sent to shareholders to inform them of the meeting and solicit their votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-24 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.